Erleada

Chemical Nameapalutamide
Dosage FormTablet (oral; 60 mg)
Drug ClassInhibitors
SystemMale reproductive
CompanyJanssen Biotech
Approval Year2018

Indication

  • Erleada is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.
  • Erleada is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Last updated on 1/13/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Erleada (apalutamide) prescribing information.2019Janssen Biotech